Evaluation of antibody-dependent cell cytotoxicity (ADCC) in lung cancer cell lines treated with combined anti-EGFR and anti-PD-L1 therapy

Sparano, Francesca; Barra, Giusi; Corte, Carminia Maria Della; Liello, Raimondo Di; Fasano, Morena; Ciardiello, Fortunato; Morgillo, Floriana

doi:10.1093/annonc/mdz268.036

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The biological rational for combining Cx and immunotherapy is still not completely known, but there are multiple hypotheses on the high relevance of the immunologic activity of Cx, based on its peculiar effect of promoting a more permissive anti-tumor immune reaction through NK activation. 104 Clinical and preclinical studies have shown that immunoglobulin G1 monoclonal antibodies, such as Cx, have the highest capability for stimulating ADCC as compared with other isotypes. Cx stimulates ADCC by binding its constant region, Fc, with a natural killer (NK) cell receptor, resulting in NK cell activation.…”

Section: Perspectives: Role Of Anti-egfr Drugs In the Era Of Immunothmentioning

confidence: 99%

“…Cx stimulates ADCC by binding its constant region, Fc, with a natural killer (NK) cell receptor, resulting in NK cell activation. 104 Active NK cells can carry out their own lytic activity on tumor cells, which causes the release of tumor antigens, resulting in the activation of cytotoxic T cells by the presentation of antigens by macrophages and dendritic cells. In this manner, the crosstalk between immune cells and the continuous release of antigens lead to the activation of both innate and adaptive immune systems.…”

Section: Perspectives: Role Of Anti-egfr Drugs In the Era Of Immunothmentioning

confidence: 99%

See 1 more Smart Citation

Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy

et al. 2021

View full text Add to dashboard Cite

Head and neck cancers (HNC) represent the seventh most frequent cancer worldwide, with squamous cell carcinomas as the most frequent histologic subtype. Standard treatment for early stage diseases is represented by single modality surgery or radiotherapy, whereas in the locally advanced and recurrent or metastatic settings a more aggressive multi-modal approach is needed with locoregional intervention and/or systemic therapies. Epidermal Growth Factor Receptor (EGFR) plays an important role in HNC biology and has been studied extensively in preclinical and clinical settings. In this scenario, anti-EGFR targeted agent cetuximab, introduced in clinical practice a decade ago, represents the only approved targeted therapy to date, while the development of immune-checkpoint inhibitors has recently changed the available treatment options. In this review, we focus on the current role of anti-EGFR therapies in HNCs, underlying available clinical data and mechanisms of resistance, and highlight future perspectives regarding their role in the era of immunotherapy.

show abstract

Section: Perspectives: Role Of Anti-egfr Drugs In the Era Of Immunothmentioning

confidence: 99%

Section: Perspectives: Role Of Anti-egfr Drugs In the Era Of Immunothmentioning

confidence: 99%